Global Aptamers Market Size, Share, and COVID-19 Impact Analysis, By Type (RNA, DNA, and XNA), By Technology (SELEX, X-aptamers, and MARAS Technique), By Application (Diagnostics, Therapeutics Development, Research & Development, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033

Industry: Healthcare

RELEASE DATE Feb 2024
REPORT ID SI3636
PAGES 200
REPORT FORMAT PathSoft

Global Aptamers Market Insights Forecasts to 2033

  • The Global Aptamers Market Size was Valued at USD 2.86 Billion in 2023.
  • The Market Size is Growing at a CAGR of 19.7% from 2023 to 2033.
  • The Worldwide Aptamers Market Size is Expected to Reach USD 17.3 Billion by 2033.
  • Asia Pacific is expected to grow the fastest during the forecast period.

Global Aptamers Market

Get more details on this report -

Request Free Sample PDF

The Global Aptamers Market Size is Anticipated to Exceed USD 17.3 Billion by 2033, Growing at a CAGR of 19.7% from 2023 to 2033.

 

Market Overview

A unique family of nucleic acid molecules called aptamers is being investigated for therapeutic uses. These micro-RNA/DNA molecules are the chemical counterparts of antibodies since they can create secondary and tertiary structures that can bind proteins or other biological targets precisely. Because aptamers have a propensity to form both single-stranded loops and helices, they can take on a multitude of forms. These may be further designed to have improved specificity and affinity. They are readily synthesized, and they are used in the inhibition and characterization of proteins. These adaptable molecules bind a wide range of substances, including proteins, peptides, macromolecules, poisons, carbohydrates, and even living cells. Healthcare practitioners are being encouraged to utilize aptamer-based treatments as a primary treatment option to shorten recovery times due to a growing understanding of the advantages of aptamer over antibodies. Aptamers are widely used in cancer therapies to deliver the medication to specific target cells. The global aptamers market growth is being driven by an increase in the prevalence of chronic and cardiovascular illnesses.

 

Report Coverage

This research report categorizes the market for the global aptamers market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global aptamers market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global aptamers market.

 

Global Aptamers Market Report Coverage

Report CoverageDetails
Base Year:2023
Market Size in 2023:USD 2.86 Billion
Forecast Period:2023-2033
Forecast Period 2023-2033 CAGR:19.7%
2033 Value Projection:USD 17.3 Billion
Historical Data for:2019-2022
No. of Pages:200
Tables, Charts & Figures:115
Segments covered:By Type, By Technology, By Application, By Region
Companies Covered:NOXXON Pharma, Vivonics Inc., 2bind GmbH, TriLink BioTechnologies, Donovan Biotechnology, LLC, SomaLogic, Inc., ATDBio Ltd, NeoVentures Biotechnology Inc., Base Pair Biotechnologies, Barrick Lab, APTATARGETS SL, Creative Biogene, Aptamer Group, Aptamer Sciences, Inc., Aptagen, LLC, IBA GmbH, KANEKA CORPORATION, AMS Biotechnology Limited, AuramerBio, NOVAPTECH, and other key companies.
Pitfalls & Challenges:Covid-19 Empact,Challenges,Growth, Analysis.

Get more details on this report -

Request Free Sample PDF
 

Driving Factors

The global aptamers market is expected to grow as a result of the increasing number of FDA approvals for aptamers, growing public demand for aptamers due to their advantages over antibodies, increased awareness among market participants, encouraging pipeline, and rapid adoption of aptamers in the food and chemical industries. The market for aptamers is rising at a faster rate due to the increasing acceptance of technological developments. In comparison to antibodies, they are less expensive and more effective at binding to big compounds. Market expansion is mostly driven by rising R&D expenditures for aptamer development and applications. Pharmaceutical businesses, biotechnology companies, academic institutions, and government organizations have made many R&D expenditures in the aptamers industry in recent years, and it is expected that these trends will keep going in the forecast period.

 

Restraining Factors

The market growth for aptamers is further hampered by the high costs of aptamer development, optimization, and manufacturing; the regulatory environment for aptamers is difficult; there are few commercially viable aptamers available; and aptamers compete with other well-established technologies like peptides, small molecules, and antibodies. One of the main things impeding the growth of the aptamers market is the lack of knowledge among researchers, end users, and healthcare professionals regarding the possible uses and advantages of aptamers. Other major barriers to the aptamers market's rapid expansion include production stability and problems, a narrow target variety, IP issues, strict quality control requirements, and ethical and safety concerns.

 

Market Segmentation

The Global Aptamers Market share is classified into type, technology, application

  • The DNA segment is expected to hold the largest share of the global aptamers market during the forecast period.   

Based on the type, the global aptamers market is divided into RNA, DNA, and XNA. Among these, the DNA segment is expected to hold the largest share of the global aptamers market during the forecast period. This is because the cost of producing DNA aptamers is cheaper than that of RNA and XNA aptamers, among other aptamer kinds. The DNA segment dominating the market is because they are more robust than other kinds of aptamers.

 

  • The SELEX segment is expected to hold the largest share of the global aptamers market during the forecast period.    

Based on the technology, the global aptamers market is divided into SELEX, X-aptamers, and MARAS technique. Among these, the SELEX segment is expected to hold the largest share of the global aptamers market during the forecast period. This is because, in comparison to other methods, SELEX offers better efficiency, simpler enzymatic processes, and quicker selection. Extended developments in SELEX approaches and personalization strategies have drawn interest from academic and business stakeholders.

 

  • The therapeutics segment is expected to grow at the greatest pace in the global aptamers market during the forecast period.

Based on the application, the global aptamers market is divided into diagnostics, therapeutics development, research & development, and others. Among these, the therapeutics segment is expected to grow at the greatest pace in the global aptamers market during the forecast period. This is because more clinical research is being done to assess aptamers for potential new medications, and aptamer businesses are collaborating with well-known pharmaceutical and biotechnology companies.

 

Regional Segment Analysis of the Global Aptamers Market

  • North America (U.S., Canada, Mexico) 
  • Europe (Germany, France, the U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Rest of APAC)
  • South America (Brazil and the Rest of South America) 
  • The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the global aptamers market over the predicted timeframe.

North America is anticipated to hold the largest share of the global aptamers market over the predicted timeframe. This is because there is a higher focus on drug discovery and development, there is a rise in aptamer research and development activities, and aptamer-based goods and therapies are being developed. The North American aptamer business is expanding through to public support, research organizations, and R&D facilities. Furthermore, the United States leads the market in North America because of supportive government programs and a growing number of research facilities. Accessibility and well-established healthcare infrastructures are significant factors of the global aptamers market value in the region.

 

Asia Pacific is expected to grow at the fastest pace in the global aptamers market during the forecast period. The requirement for aptamers in the area is being driven by the increased emphasis on medication research and discovery. The region's aptamers market is expanding as a result of encouraging government efforts as well as rising investments in the biotechnology and pharmaceutical sectors. Due to increased R&D efforts, the creation of aptamer-based goods, a greater emphasis on medication research and development, the approval of novel aptamer-based medicines, and supportive government initiatives, Asia Pacific is anticipated to expand at the greatest pace in the global aptamers market.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global aptamers along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

  • NOXXON Pharma
  • Vivonics Inc.
  • 2bind GmbH
  • TriLink BioTechnologies
  • Donovan Biotechnology, LLC
  • SomaLogic, Inc.
  • ATDBio Ltd
  • NeoVentures Biotechnology Inc.
  • Base Pair Biotechnologies
  • Barrick Lab
  • APTATARGETS SL
  • Creative Biogene
  • Aptamer Group
  • Aptamer Sciences, Inc.
  • Aptagen, LLC
  • IBA GmbH
  • KANEKA CORPORATION
  • AMS Biotechnology Limited
  • AuramerBio
  • NOVAPTECH

 

Key Target Audience

  • Market Players
  • Investors
  • End-users
  • Government Authorities 
  • Consulting And Research Firm
  • Venture capitalists
  • Value-Added Resellers (VARs)

 

Recent Developments

  • In January 2024, the leader in cutting-edge biotechnology solutions, Creative Biogene, announced the extension of its stable high-quality cell lines for use in cellular tests for antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).

 

  • In January 2023, Aptamer Group and BaseCure Therapeutics collaborated on the creation of novel targeted gene treatments. Through this collaboration, particular cell types that might be used as possible delivery systems for siRNA absorption into target cells and tissues are identified. By using this tactic, the business was able to generate fresh prospects for the growth of aptamer applications in the pharmaceutical industry.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Global Aptamers Market based on the below-mentioned segments: 

 

Global Aptamers Market, By Type

  • RNA
  • DNA
  • XNA

 

Global Aptamers Market, By Technology

  • SELEX
  • X-aptamers
  • MARAS Technique

 

Global Aptamers Market, By Application

  • Diagnostics
  • Therapeutics Development
  • Research & Development
  • Others

 

Global Aptamers Market, By Region

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • Uk
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Qatar
    • South Africa
    • Rest of the Middle East & Africa

Frequently Asked Questions (FAQ)

  • 1. Which are the key companies that are currently operating within the market?
    NOXXON Pharma, Vivonics Inc., 2bind GmbH, TriLink BioTechnologies, Donovan Biotechnology, LLC, SomaLogic, Inc., ATDBio Ltd, NeoVentures Biotechnology Inc., Base Pair Biotechnologies, Barrick Lab, APTATARGETS SL, Creative Biogene, Aptamer Group, Aptamer Sciences, Inc., Aptagen, LLC, IBA GmbH, KANEKA CORPORATION, AMS Biotechnology Limited, AuramerBio, NOVAPTECH, and others.
  • 2. What is the size of the global aptamers market?
    The Global Aptamers Market is expected to grow from USD 2.86 Billion in 2023 to USD 17.3 Billion by 2033, at a CAGR of 19.7% during the forecast period 2023-2033.
  • 3. Which region is holding the largest share of the market?
    North America is anticipated to hold the largest share of the global aptamers market over the predicted timeframe.

Need help to buy this report?

Inquiry Before Buy
We'll use cookies to improve and customize your experience if you continue to browse. Is it OK if we also use cookies to show you personalized ads?
Learn more and manage your cookies
Yes, Accept Cookies